INCLISIRAN REDUCES LDL-CHOLESTEROL INDEPENDENT OF GENOTYPE IN SUBJECTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA

被引：0

作者：

Raal, F. J. ^{[1
]}

Kallend, D. ^{[2
]}

Ray, K. K. ^{[3
]}

Turner, T. A. ^{[4
]}

Koenig, W. ^{[5
]}

Wright, R. S. ^{[6
,7
]}

Wijngaard, P. L. ^{[8
]}

Curcio, D. ^{[8
]}

Jaros, M. J. ^{[9
]}

Leiter, L. A. ^{[10
]}

Landmesser, U. ^{[11
]}

Kastelein, J. J. ^{[12
]}

机构：

[1] Univ Witwatersrand, Fac Hlth Sci, Johannesburg, South Africa

[2] DalCor Pharmaceut, Pharmacol & Pharmacotherapy, Montreal, PQ, Canada

[3] Imperial Coll London, Ctr Cardiovasc Dis Prevent, London, England

[4] Lipid Clin, Metab & Atherosclerosis Res Ctr, Cincinnati, OH USA

[5] Tech Univ Munich, Deutsch Herzzentrum Munchen, Munich, Germany

[6] Mayo Clin, Div Prevent Cardiol, Rochester, MN USA

[7] Mayo Clin, Dept Cardiol, Rochester, MN USA

[8] Medicines Co, Parsippany, NJ USA

[9] Summit Analyt, Biostat, Denver, CO USA

[10] Li Ka Shing Knowledge Inst, Clin Nutr & Risk Factor Modificat Ctr, Toronto, ON, Canada

[11] Charite Univ Med Berlin, Cardiol, Berlin, Germany

[12] Univ Amsterdam, Acad Med Ctr, Vasc Med, Amsterdam, Netherlands

来源：

ATHEROSCLEROSIS | 2020年 / 315卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1707

引用

页码：E7 / E8

页数：2

共 50 条

[1] Anacetrapib reduces LDL cholesterol in patients with heterozygous familial hypercholesterolaemia
[J]. Nature Reviews Cardiology, 2015, 12 (5) : 261 - 261
[2] The effect of adjusting LDL-cholesterol for Lipoprotein(a)-cholesterol on the diagnosis of Familial Hypercholesterolaemia
Thayabaran, D.
Tsui, A. P. T.
Ebmeier, S. J.
Cegla, J.
David, A.
Jones, B.
[J]. ATHEROSCLEROSIS PLUS, 2022, 49 : S3 - S3
[3] The effect of adjusting LDL-cholesterol for Lp(a)-cholesterol on the diagnosis of familial hypercholesterolaemia
Thayabaran, Darmiga
Tsui, Anson P. T.
Ebmeier, Stefan
Cegla, Jaimini
David, Alessia
Jones, Ben
[J]. JOURNAL OF CLINICAL LIPIDOLOGY, 2023, 17 (02) : 244 - 254
[4] Inclisiran (Leqvio) for LDL-Cholesterol Lowering
不详
[J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2022, 64 (1646): : 43 - 45
[5] Plasma lipoprotein (a) levels and LDL-cholesterol lowering response to statin therapy in patients with heterozygous familial hypercholesterolaemia
Miltiadous, G.
Cariolou, M.
Mitrogianni, Z. O. I.
Doumas, M.
Saougkos, V.
Bairaktari, E.
Elisaf, M.
[J]. ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 530 - 530
[6] Impact of statin therapy on LDL and non-HDL cholesterol levels in subjects with heterozygous familial hypercholesterolaemia
Climent, Elisenda
Marco-Benedi, Victoria
Benaiges, David
Pinto, Xavier
Suarez-Tembra, Manuel
Plana, Nuria
Lafuente, Hannia
Ortega-Martinez de Victoria, Emilio
Brea-Hernando, Angel
Vila, Alex
Civeira, Fernando
Pedro-Botet, Juan
[J]. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2021, 31 (05) : 1594 - 1603
[7] RELATIONSHIP BETWEEN MEASUREMENTS OF NON-HDL-CHOLESTEROL AND LDL-CHOLESTEROL IN FAMILIAL HYPERCHOLESTEROLAEMIA
Abreu, J.
Haralambos, K.
Ashfield-Watt, P.
Edwards, R.
Gingell, R.
Townsend, D.
Datta, D.
McDowell, I. F. W.
[J]. ATHEROSCLEROSIS, 2016, 245 : E247 - E247
[8] LDL receptor mutation genotype and vascular disease phenotype in heterozygous familial hypercholesterolaemia
Brorholt-Petersen, JU
Jensen, HK
Jensen, JM
Refsgaard, J
Christiansen, T
Hansen, LB
Gregersen, N
Faergeman, O
[J]. CLINICAL GENETICS, 2002, 61 (06) : 408 - 415
[9] Guggulipid raises LDL-cholesterol levels in hypercholesterolaemia
[J]. Reactions Weekly, 2003, 965 (1) : 5 - 5
[10] Lipoprotein(a), LDL-cholesterol, and hypertension: predictors of the need for aortic valve replacement in familial hypercholesterolaemia
Perez de Isla, Leopoldo
Watts, Gerald F.
Alonso, Rodrigo
Luis Diaz-Diaz, Jose
Muniz-Grijalvo, Ovidio
Zambon, Daniel
Fuentes, Francisco
de Andres, Raimundo
Padro, Teresa
Lopez-Miranda, Jose
Mata, Pedro
[J]. EUROPEAN HEART JOURNAL, 2021, 42 (22) : 2201 - 2211

← 1 2 3 4 5 →